Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers using high-performance liquid chromatography coupled to tandem mass spectrometry |
| |
Authors: | Gustavo D. Mendes Thais da Silva Pereira Júlio César Rodrigues Elaine Marcílio Santos Mariani Rafaela Souza Rodrigo Alvaro Brandão Lopes-Martins Natalícia de Jesus Antunes Ronilson Agnaldo Moreno Gilberto De Nucci |
| |
Affiliation: | 1. Programa de Mestrado Profissional de Saúde e Meio Ambiente da Universidade Metropolitana de Santos, Santos, Brazil;2. Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas/SP, Brazil;3. Laboratory of Biophotonics and Experimental Therapeutics, Instituto de Pesquisa & Desenvolvimento – IP&D, Universidade do Vale do Paraíba, São José dos Campos, Brazil;4. Galeno Desenvolvimento de Pesquisas Ltda, Campinas, Brazil |
| |
Abstract: | To assess the bioequivalence of two zolpidem hemitartrate formulations in 30 healthy volunteers. Plasma samples were obtained over a 24 h period. Plasma concentrations of zolpidem were analyzed by liquid chromatography coupled to tandem mass spectrometry with positive ion electrospray ionization using multiple reaction monitoring. Values of peak concentration (Cmax), area under curve (AUC), half-life, elimination constant, volume of distribution and clearance showed statistically significant differences when comparing women (604.34 ng h/ml, 127.36 ng/ml, 4.4 h, 0.18 1/h, 50.56 L and 8.55 L/h, respectively) and men (276.1 ng h/ml, 70.9 ng/ml, 3.3 h, 0.26 1/h, 91.42 L and 24.34 L/h, respectively), receiving the same dose (5 mg), respectively. The geometric means with corresponding 90% confidence interval for Test/Reference percentage ratios were 99.73% (CI 93.69–106.16) for Cmax, 97.44% (90% CI = 91.85–103.37%) for area under curve of plasma concentration until the last concentration observed (AUClast) and 98.30% (90% CI = 92.48–104.49) for the area under curve between the first sample (pre-dosage) and infinity (AUC0–inf). Since the 90% CI for AUClast, AUC0–inf and Cmax ratios were within the 80–125% interval proposed by the US Food and Drug Administration, it was concluded that zolpidem hemitartrate formulation (5 mg orodispersible tablet) is bioequivalent to the zolpidem hemitartrate formulation (Patz SL 5 mg sublingual tablet) with regard to both the rate and the extent of absorption. A new formulation of zolpidem 2.5 mg may be useful in women for the same clinical benefits as the 5 mg formulation in men. |
| |
Keywords: | bioavailability LC/MS/MS pharmacokinetics tandem mass spectrometry |
|
|